The Sapheon Closure System Feasibility Study

This is an interventional treatment trial for Venous Insufficiency of Leg Read More

Inclusion Criteria:

• Males or non-pregnant females ≥21 years of age but <76 years of age.
• Venous reflux disease in the GSV diagnosed by clinical symptoms, with or without visible varicosities, and confirmed by duplex ultrasound imaging.
• Candidate for surgical closure of a segment of the GSV.
• CEAP classification of C2, C3 or C4.
• Ability to walk unassisted.
• Life expectancy of at least 18 months.
• Weight >110 lbs. (50 kg).
• Ability to attend follow-up visits.
• Ability to understand the investigational nature of the treatment, and to provide written informed consent.

Exclusion Criteria:

• Previous surgical procedure (surgical, thermal, or chemical ablation) associated with the venous segment to be treated.
• Diameter of index vein (Supine) <3mm or >12 mm in any segment.
• Tortuous GSV, which in the opinion of the Investigator will limit catheter placement.
• Local or systemic infection.
• Insulin dependent diabetes.
• Leg obesity impairing the ability to gain access to the treatment leg, and/or apply sufficient compression for treatment.
• Documented history of superficial or deep thrombophlebitis.
• Varicosities secondary to pelvic or abdominal tumor.
• Significant arterial insufficiency; demonstrated by absence of ankle pulse.
• Known sensitivity to the cyanoacrylate (CA) adhesive or positive reaction just prior to surgery (by injecting a small peripheral vein with the agent). The Study surgeon will judge the need for the injection and the subject's reaction to the injection on clinical grounds.
• Formal duplication of the saphenous trunk in the index vein (Accessory GSV segments allowed).
• Hypercoaguable state.
• Presence of incompetent perforators in the treatment length.
• History of right ventricular failure.
• Significant femoral or popliteal vein insufficiency.
• BMI >35
• Additional procedures in the treatment leg likely required within the six months after the investigational procedure.
• Current participation in another clinical study involving an investigational agent or treatment, or within the 30 days prior to enrollment.
• Other concurrent medical or other condition (chronic or acute in nature) that in the opinion of the Investigator may prevent safe participation or otherwise render the subject ineligible for the Study.